|
GS185131: GO:0044699 single-organism process
|
|
GS207306: GO:0080134 regulation of response to stress
|
|
GS198398: GO:0050670 regulation of lymphocyte proliferation
|
|
GS164444: MP:0005197 abnormal uvea morphology
|
|
GS122866: Polysaccharides interacting genes (MeSH:D011134) in CTD
|
|
GS170247: MP:0002038 carcinoma
|
|
GS170447: MP:0010210 abnormal circulating cytokine level
|
|
GS182704: GO:0051172 negative regulation of nitrogen compound metabolic process
|
|
GS124545: Amphotericin B interacting genes (MeSH:D000666) in CTD
|
|
GS206380: GO:0001763 morphogenesis of a branching structure
|
|
GS208257: GO:0016064 immunoglobulin mediated immune response
|
|
GS184458: GO:0009892 negative regulation of metabolic process
|
|
GS192324: GO:0050727 regulation of inflammatory response
|
|
GS122940: Dimethylnitrosamine interacting genes (MeSH:D004128) in CTD
|
|
GS191625: GO:0040007 growth
|
|
GS188071: GO:0042176 regulation of protein catabolic process
|
|
GS205081: GO:0032715 negative regulation of interleukin-6 production
|
|
GS168559: MP:0002421 abnormal cell-mediated immunity
|
|
GS169830: MP:0005384 cellular phenotype
|
|
GS166949: MP:0009308 adenocarcinoma
|
|
GS170667: MP:0010080 abnormal hepatocyte physiology
|
|
GS191193: GO:0009607 response to biotic stimulus
|
|
GS202544: GO:0032655 regulation of interleukin-12 production
|
|
GS169029: MP:0005554 decreased circulating creatinine level
|
|
GS123199: Tobacco Smoke Pollution interacting genes (MeSH:D014028) in CTD
|
|
GS163905: MP:0000493 rectal prolapse
|
|
GS182241: GO:0043068 positive regulation of programmed cell death
|
|
GS207674: GO:0002697 regulation of immune effector process
|
|
GS206098: GO:0002263 cell activation involved in immune response
|
|
GS195083: GO:0007267 cell-cell signaling
|
|
GS124517: ONO-AE1-329 interacting genes (MeSH:C461399) in CTD
|
|
GS163666: MP:0005278 abnormal cholesterol homeostasis
|
|
GS201231: GO:0060548 negative regulation of cell death
|
|
GS123134: Forskolin interacting genes (MeSH:D005576) in CTD
|
|
GS123450: 4-phenylenediamine interacting genes (MeSH:C029728) in CTD
|
|
GS206817: GO:0032640 tumor necrosis factor production
|
|
GS122521: Nitric Oxide interacting genes (MeSH:D009569) in CTD
|
|
GS199041: GO:0045349 interferon-alpha biosynthetic process
|
|
GS168334: MP:0002619 abnormal lymphocyte morphology
|
|
GS169842: MP:0004392 abnormal CD8-positive T cell physiology
|
|
GS187887: GO:0080090 regulation of primary metabolic process
|
|
GS136080: juvenile cystic kidney modifier 2 (Jckm2, Published QTL Chr 1)
|
|
GS165992: MP:0008469 abnormal protein level
|
|
GS191035: GO:0005125 cytokine activity
|
|
GS121804: Ro 41-5253 interacting genes (MeSH:C084904) in CTD
|
|
GS166858: MP:0000685 abnormal immune system morphology
|
|
GS164893: MP:0003075 altered response to CNS ischemic injury
|
|
GS165564: MP:0008120 abnormal myeloid dendritic cell number
|
|
GS166749: MP:0002221 abnormal lymph organ size
|
|
GS163010: MP:0011181 increased hematopoietic cell number
|
|
GS126646: Carbon Tetrachloride interacting genes (MeSH:D002251) in CTD
|
|
GS206108: GO:2001141 regulation of RNA biosynthetic process
|
|
GS207473: GO:0033157 regulation of intracellular protein transport
|
|
GS184917: GO:0002252 immune effector process
|
|
GS198029: GO:0051651 maintenance of location in cell
|
|
GS200210: GO:0002676 regulation of chronic inflammatory response
|
|
GS181414: GO:0032880 regulation of protein localization
|
|
GS177265: GO:0048731 system development
|
|
GS167214: MP:0005319 abnormal enzyme/ coenzyme level
|
|
GS207925: GO:0034645 cellular macromolecule biosynthetic process
|
|
GS165136: MP:0003009 abnormal cytokine secretion
|
|
GS181893: GO:0048522 positive regulation of cellular process
|
|
GS165874: MP:0002133 abnormal respiratory system physiology
|
|
GS165194: MP:0001533 abnormal skeleton physiology
|
|
GS167383: MP:0005328 abnormal circulating creatinine level
|
|
GS126466: Quercetin interacting genes (MeSH:D011794) in CTD
|
|
GS183543: GO:0051179 localization
|
|
GS122239: Cefuroxime interacting genes (MeSH:D002444) in CTD
|
|
GS166547: MP:0008662 abnormal interleukin-12 secretion
|
|
GS162953: MP:0002020 increased tumor incidence
|
|
GS202162: GO:0005126 cytokine receptor binding
|
|
GS202527: GO:0032386 regulation of intracellular transport
|
|
GS193414: GO:0044249 cellular biosynthetic process
|
|
GS123943: Curcumin interacting genes (MeSH:D003474) in CTD
|
|
GS187861: GO:0032689 negative regulation of interferon-gamma production
|
|
GS124239: Gonadal Steroid Hormones interacting genes (MeSH:D012739) in CTD
|
|
GS194599: GO:0002902 regulation of B cell apoptotic process
|
|
GS206264: GO:0044116 growth of symbiont involved in interaction with host
|
|
GS135642: chronic kidney disease blood pressure locus 1 (Ckdbp1, Published QTL Chr 1)
|
|
GS166565: MP:0000693 spleen hyperplasia
|
|
GS180114: GO:0044419 interspecies interaction between organisms
|
|
GS35289: Whole Brain Gene expression correlates of Prepulse inhibition at 80db in Females & Males BXD
|
|
GS202796: GO:0051046 regulation of secretion
|
|
GS203970: GO:0046209 nitric oxide metabolic process
|
|
GS135622: cholesterol 7 (Chol7, Published QTL Chr 1)
|
|
GS205659: GO:0042493 response to drug
|
|
GS184456: GO:0009894 regulation of catabolic process
|
|
GS197348: GO:0050777 negative regulation of immune response
|
|
GS163994: MP:0008248 abnormal mononuclear phagocyte morphology
|
|
GS193298: GO:0002861 regulation of inflammatory response to antigenic stimulus
|
|
GS125752: 1,6-hexamethylene diisocyanate interacting genes (MeSH:C015262) in CTD
|
|
GS193550: GO:0002274 myeloid leukocyte activation
|
|
GS125418: adenosine 5'-O-(3-thiotriphosphate) interacting genes (MeSH:C022571) in CTD
|
|
GS197754: GO:0042533 tumor necrosis factor biosynthetic process
|
|
GS209170: GO:0033619 membrane protein proteolysis
|
|
GS123006: Tetanus Toxoid interacting genes (MeSH:D013745) in CTD
|
|
GS126023: oxymatrine interacting genes (MeSH:C037573) in CTD
|
|
GS167580: MP:0008617 increased circulating interleukin-12 level
|
|
GS136382: obesity and body weight QTL 1 (Obwq1, Published QTL Chr 1)
|
|
GS206237: GO:0042981 regulation of apoptotic process
|
|
GS121412: Mycophenolic Acid interacting genes (MeSH:D009173) in CTD
|
|
GS164042: MP:0002018 malignant tumors
|
|
GS166409: MP:0002114 abnormal axial skeleton morphology
|
|
GS201696: GO:0010941 regulation of cell death
|
|
GS206265: GO:0044117 growth of symbiont in host
|
|
GS201367: GO:0019538 protein metabolic process
|
|
GS182982: GO:0043066 negative regulation of apoptotic process
|
|
GS210704: GO:0032635 interleukin-6 production
|
|
GS167127: MP:0005280 abnormal fatty acid level
|
|
GS195340: GO:0045893 positive regulation of transcription, DNA-dependent
|
|
GS122473: Ciprofloxacin interacting genes (MeSH:D002939) in CTD
|
|
GS202468: GO:0070887 cellular response to chemical stimulus
|
|
GS182703: GO:0051171 regulation of nitrogen compound metabolic process
|
|
GS203482: GO:0044093 positive regulation of molecular function
|
|
GS186790: GO:0006725 cellular aromatic compound metabolic process
|
|
GS163850: MP:0001542 abnormal bone strength
|
|
GS169075: MP:0002078 abnormal glucose homeostasis
|
|
GS168683: MP:0000598 abnormal liver morphology
|
|
GS165738: MP:0008476 increased spleen red pulp amount
|
|
GS204150: GO:0009611 response to wounding
|
|
GS126828: Glucocorticoids interacting genes (MeSH:D005938) in CTD
|
|
GS167896: MP:0009355 increased liver triglyceride level
|
|
GS166118: MP:0002109 abnormal limb morphology
|
|
GS200341: GO:0051179 localization
|
|
GS210464: GO:0060711 labyrinthine layer development
|
|
GS189751: GO:0050794 regulation of cellular process
|
|
GS164323: MP:0000511 abnormal intestinal mucosa morphology
|
|
GS195668: GO:0042221 response to chemical stimulus
|
|
GS136668: skin tumor susceptibility 8 (Skts8, Published QTL Chr 1)
|
|
GS165171: MP:0008835 abnormal intercellular signaling peptide or protein level
|
|
GS189510: GO:0001763 morphogenesis of a branching structure
|
|
GS209010: GO:1901575 organic substance catabolic process
|
|
GS189140: GO:0030889 negative regulation of B cell proliferation
|
|
GS194735: GO:0030163 protein catabolic process
|
|
GS200566: GO:0019724 B cell mediated immunity
|
|
GS180036: GO:0032501 multicellular organismal process
|
|
GS195710: GO:0032268 regulation of cellular protein metabolic process
|
|
GS196930: GO:0065007 biological regulation
|
|
GS200312: GO:0019219 regulation of nucleobase-containing compound metabolic process
|
|
GS177859: GO:0045944 positive regulation of transcription from RNA polymerase II promoter
|
|
GS205998: GO:0030885 regulation of myeloid dendritic cell activation
|
|
GS210574: GO:0002712 regulation of B cell mediated immunity
|
|
GS195660: GO:0061138 morphogenesis of a branching epithelium
|
|
GS169303: MP:0008250 abnormal myeloid leukocyte morphology
|
|
GS168407: MP:0005465 abnormal T-helper 1 physiology
|
|
GS167542: MP:0001790 abnormal immune system physiology
|
|
GS203058: GO:0048519 negative regulation of biological process
|
|
GS197244: GO:0044237 cellular metabolic process
|
|
GS201264: GO:0009890 negative regulation of biosynthetic process
|
|
GS188227: GO:0032715 negative regulation of interleukin-6 production
|
|
GS163083: MP:0010279 increased gastrointestinal tumor incidence
|
|
GS208562: GO:0040008 regulation of growth
|
|
GS209284: GO:0010627 regulation of intracellular protein kinase cascade
|
|
GS203373: GO:0002683 negative regulation of immune system process
|
|
GS125802: Asbestos, Serpentine interacting genes (MeSH:D017632) in CTD
|
|
GS165418: MP:0002490 abnormal immunoglobulin level
|
|
GS210285: GO:0071887 leukocyte apoptotic process
|
|
GS166649: MP:0011504 abnormal limb long bone morphology
|
|
GS170779: MP:0000182 increased circulating LDL cholesterol level
|
|
GS201262: GO:0009892 negative regulation of metabolic process
|
|
GS163412: MP:0004016 decreased bone mass
|
|
GS170782: MP:0000181 abnormal circulating LDL cholesterol level
|
|
GS178589: GO:0045893 positive regulation of transcription, DNA-dependent
|
|
GS122625: beta-Lactams interacting genes (MeSH:D047090) in CTD
|
|
GS169037: MP:0010183 abnormal CD4-positive helper T cell morphology
|
|
GS170360: MP:0001828 abnormal T cell activation
|
|
GS124150: sodium bichromate interacting genes (MeSH:C016104) in CTD
|
|
GS124301: N-chlorotaurine interacting genes (MeSH:C043410) in CTD
|
|
GS136152: limb length QTL 1 (Lmblgq1, Published QTL Chr 1)
|
|
GS123854: Cyclophosphamide interacting genes (MeSH:D003520) in CTD
|
|
GS162933: MP:0005636 abnormal mineral homeostasis
|
|
GS177990: GO:0030163 protein catabolic process
|
|
GS122365: Suramin interacting genes (MeSH:D013498) in CTD
|
|
GS169777: MP:0002398 abnormal bone marrow cell morphology/development
|
|
GS169748: MP:0008577 increased circulating interferon-gamma level
|
|
GS204158: GO:0032800 receptor biosynthetic process
|
|
GS199986: GO:0009719 response to endogenous stimulus
|
|
GS126780: S-Nitrosoglutathione interacting genes (MeSH:D026422) in CTD
|
|
GS122841: beta-Glucans interacting genes (MeSH:D047071) in CTD
|
|
GS168342: MP:0008752 abnormal tumor necrosis factor level
|
|
GS195457: GO:0060341 regulation of cellular localization
|
|
GS169409: MP:0004939 abnormal B cell morphology
|
|
GS126432: Dydrogesterone interacting genes (MeSH:D004394) in CTD
|
|
GS201848: GO:0048598 embryonic morphogenesis
|
|
GS197024: GO:0051045 negative regulation of membrane protein ectodomain proteolysis
|
|
GS166994: MP:0008721 abnormal chemokine level
|
|
GS166828: MP:0010871 abnormal trabecular bone mass
|
|
GS210580: GO:0002718 regulation of cytokine production involved in immune response
|
|
GS164443: MP:0005196 abnormal posterior uvea morphology
|
|
GS166250: MP:0008247 abnormal mononuclear cell morphology
|
|
GS210084: GO:0044144 modulation of growth of symbiont involved in interaction with host
|
|
GS126950: zoledronic acid interacting genes (MeSH:C088658) in CTD
|
|
GS167587: MP:0009813 abnormal leukotriene level
|
|
GS187420: GO:0031644 regulation of neurological system process
|
|
GS188506: GO:0010467 gene expression
|
|
GS193343: GO:0071887 leukocyte apoptotic process
|
|
GS206201: GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB cascade
|
|
GS208012: GO:0044464 cell part
|
|
GS125511: Vanadium interacting genes (MeSH:D014639) in CTD
|
|
GS183422: GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
|
|
GS187113: GO:0005615 extracellular space
|
|
GS189324: GO:0048585 negative regulation of response to stimulus
|
|
GS201239: GO:0046483 heterocycle metabolic process
|
|
GS193929: GO:0042098 T cell proliferation
|
|
GS188763: GO:0009888 tissue development
|
|
GS192073: GO:1901576 organic substance biosynthetic process
|
|
GS188399: GO:0044238 primary metabolic process
|
|
GS162983: MP:0002356 abnormal spleen red pulp morphology
|
|
GS167056: MP:0004686 decreased length of long bones
|
|
GS208060: GO:0010557 positive regulation of macromolecule biosynthetic process
|
|
GS167561: MP:0008808 decreased spleen iron level
|
|
GS184435: GO:0046483 heterocycle metabolic process
|
|
GS122784: Terbutaline interacting genes (MeSH:D013726) in CTD
|
|
GS210100: GO:0032945 negative regulation of mononuclear cell proliferation
|
|
GS168422: MP:0000716 abnormal immune system cell morphology
|
|
GS181032: GO:0001701 in utero embryonic development
|
|
GS192090: GO:0019233 sensory perception of pain
|
|
GS165320: MP:0008669 increased interleukin-12b secretion
|
|
GS122443: Morphine interacting genes (MeSH:D009020) in CTD
|
|
GS123554: vinclozolin interacting genes (MeSH:C025643) in CTD
|
|
GS166567: MP:0000691 enlarged spleen
|
|
GS186214: GO:0048518 positive regulation of biological process
|
|
GS196918: GO:0048870 cell motility
|
|
GS202556: GO:0043434 response to peptide hormone stimulus
|
|
GS162932: MP:0005637 abnormal iron homeostasis
|
|
GS166556: MP:0008668 abnormal interleukin-12b secretion
|
|
GS205623: GO:0009888 tissue development
|
|
GS193564: GO:0043901 negative regulation of multi-organism process
|
|
GS184220: GO:0071702 organic substance transport
|
|
GS163262: MP:0003763 abnormal thymus physiology
|
|
GS163277: MP:0011049 impaired adaptive thermogenesis
|
|
GS123718: Ethinyl Estradiol interacting genes (MeSH:D004997) in CTD
|
|
GS165415: MP:0002499 chronic inflammation
|
|
GS198022: GO:0002703 regulation of leukocyte mediated immunity
|
|
GS177310: GO:1901360 organic cyclic compound metabolic process
|
|
GS203755: GO:0016265 death
|
|
GS163241: MP:0002367 abnormal thymus lobule morphology
|
|
GS205053: GO:0006809 nitric oxide biosynthetic process
|
|
GS163349: MP:0008555 abnormal interferon secretion
|
|
GS167020: MP:0003956 abnormal body size
|
|
GS200016: GO:0001817 regulation of cytokine production
|
|
GS169535: MP:0005397 hematopoietic system phenotype
|
|
GS165789: MP:0005369 muscle phenotype
|
|
GS126265: Diazinon interacting genes (MeSH:D003976) in CTD
|
|
GS192959: GO:0002237 response to molecule of bacterial origin
|
|
GS169833: MP:0005380 embryogenesis phenotype
|
|
GS204096: GO:0030183 B cell differentiation
|
|
GS127019: 2-Naphthylamine interacting genes (MeSH:D015081) in CTD
|
|
GS163071: MP:0000559 abnormal femur morphology
|
|
GS191157: GO:0010558 negative regulation of macromolecule biosynthetic process
|
|
GS126764: Calcitriol interacting genes (MeSH:D002117) in CTD
|
|
GS191151: GO:0010556 regulation of macromolecule biosynthetic process
|
|
GS199850: GO:0090317 negative regulation of intracellular protein transport
|
|
GS198056: GO:0048568 embryonic organ development
|
|
GS170338: MP:0008801 abnormal erythroid progenitor cell morphology
|
|
GS209282: GO:0010628 positive regulation of gene expression
|
|
GS163667: MP:0008568 abnormal interleukin secretion
|
|
GS126206: Nicotine interacting genes (MeSH:D009538) in CTD
|
|
GS168027: MP:0000740 impaired smooth muscle contractility
|
|
GS169530: MP:0005390 skeleton phenotype
|
|
GS123002: phthalic anhydride interacting genes (MeSH:C043103) in CTD
|
|
GS123223: Minerals interacting genes (MeSH:D008903) in CTD
|
|
GS198948: GO:0006310 DNA recombination
|
|
GS200216: GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
|
|
GS199635: GO:0005622 intracellular
|
|
GS206934: GO:0051223 regulation of protein transport
|
|
GS195206: GO:0002520 immune system development
|
|
GS163591: MP:0005015 increased T cell number
|
|
GS125044: Acetaldehyde interacting genes (MeSH:D000079) in CTD
|
|
GS169227: MP:0001405 impaired coordination
|
|
GS208061: GO:0010556 regulation of macromolecule biosynthetic process
|
|
GS206406: GO:0010741 negative regulation of intracellular protein kinase cascade
|
|
GS189934: GO:0032640 tumor necrosis factor production
|
|
GS213076: Genes with suggestive difference in (B6) vs (B6PF1 + PB6F1 + PWD) comparison
|
|
GS163077: MP:0010274 increased organ/body region tumor incidence
|
|
GS206451: GO:0042089 cytokine biosynthetic process
|
|
GS196794: GO:0046907 intracellular transport
|
|
GS121552: cobaltiprotoporphyrin interacting genes (MeSH:C007095) in CTD
|
|
GS193233: GO:0031329 regulation of cellular catabolic process
|
|
GS188477: GO:0032269 negative regulation of cellular protein metabolic process
|
|
GS126895: Formaldehyde interacting genes (MeSH:D005557) in CTD
|
|
GS167323: MP:0003949 abnormal circulating lipid level
|
|
GS121486: Freund's Adjuvant interacting genes (MeSH:D005620) in CTD
|
|
GS165244: MP:0010771 integument phenotype
|
|
GS123751: Cadmium interacting genes (MeSH:D002104) in CTD
|
|
GS125729: SR 144528 interacting genes (MeSH:C110630) in CTD
|
|
GS208185: GO:0010035 response to inorganic substance
|
|
GS196941: GO:0008150 biological_process
|
|
GS198642: GO:0002874 regulation of chronic inflammatory response to antigenic stimulus
|
|
GS170368: MP:0000249 abnormal blood vessel physiology
|
|
GS183067: GO:0032101 regulation of response to external stimulus
|
|
GS127296: 1,5-anhydrofructose interacting genes (MeSH:C048927) in CTD
|
|
GS207176: GO:0050865 regulation of cell activation
|
|
GS165567: MP:0008271 abnormal bone ossification
|
|
GS166520: MP:0000479 abnormal enterocyte morphology
|
|
GS204029: GO:0010648 negative regulation of cell communication
|
|
GS207271: GO:0042742 defense response to bacterium
|
|
GS169860: MP:0008097 increased plasma cell number
|
|
GS169908: MP:0001601 abnormal myelopoiesis
|
|
GS166150: MP:0001577 anemia
|
|
GS182222: GO:0002367 cytokine production involved in immune response
|
|
GS187648: GO:0048729 tissue morphogenesis
|
|
GS189882: GO:0048545 response to steroid hormone stimulus
|
|
GS167021: MP:0003957 abnormal nitric oxide homeostasis
|
|
GS166604: MP:0005338 atherosclerotic lesions
|
|
GS198019: GO:0002706 regulation of lymphocyte mediated immunity
|
|
GS200030: GO:0032868 response to insulin stimulus
|
|
GS165134: MP:0008599 increased circulating interleukin-2 level
|
|
GS204007: GO:0044700 single organism signaling
|
|
GS126171: Capsaicin interacting genes (MeSH:D002211) in CTD
|
|
GS196282: GO:0012501 programmed cell death
|
|
GS201431: GO:0005515 protein binding
|
|
GS194367: GO:0032675 regulation of interleukin-6 production
|
|
GS162826: MP:0008539 decreased susceptibility to induced colitis
|
|
GS204146: GO:0070230 positive regulation of lymphocyte apoptotic process
|
|
GS165615: MP:0002123 abnormal hematopoiesis
|
|
GS165214: MP:0001711 abnormal placenta morphology
|
|
GS205547: GO:0042130 negative regulation of T cell proliferation
|
|
GS206192: GO:0048583 regulation of response to stimulus
|
|
GS208559: GO:0040007 growth
|
|
GS209411: GO:0048869 cellular developmental process
|
|
GS126276: pirinixic acid interacting genes (MeSH:C006253) in CTD
|
|
GS190027: GO:0006952 defense response
|
|
GS187160: GO:0044707 single-multicellular organism process
|
|
GS163314: MP:0005005 abnormal self tolerance
|
|
GS177761: GO:0044271 cellular nitrogen compound biosynthetic process
|
|
GS194636: GO:0045346 regulation of MHC class II biosynthetic process
|
|
GS195273: GO:0070727 cellular macromolecule localization
|
|
GS209613: GO:0055085 transmembrane transport
|
|
GS124951: Atrazine interacting genes (MeSH:D001280) in CTD
|
|
GS164339: MP:0002327 abnormal respiratory function
|
|
GS201372: GO:0016444 somatic cell DNA recombination
|
|
GS136815: triglyceride QTL 1 (Tglq1, Published QTL Chr 1)
|
|
GS181783: GO:0010604 positive regulation of macromolecule metabolic process
|
|
GS187128: GO:0051931 regulation of sensory perception
|
|
GS210181: GO:0031325 positive regulation of cellular metabolic process
|
|
GS198647: GO:0045926 negative regulation of growth
|
|
GS127259: glucan phosphate interacting genes (MeSH:C480175) in CTD
|
|
GS190051: GO:0051224 negative regulation of protein transport
|
|
GS202080: GO:0051252 regulation of RNA metabolic process
|
|
GS208051: GO:0002521 leukocyte differentiation
|
|
GS170635: MP:0008739 abnormal spleen iron level
|
|
GS184781: GO:0009617 response to bacterium
|
|
GS208560: GO:0032680 regulation of tumor necrosis factor production
|
|
GS164243: MP:0008588 abnormal circulating interleukin level
|
|
GS169827: MP:0005387 immune system phenotype
|
|
GS163853: MP:0001547 abnormal lipid level
|
|
GS170198: MP:0001614 abnormal blood vessel morphology
|
|
GS135829: exploratory and excitability QTL 2 (Exq2, Published QTL Chr 1)
|
|
GS163620: MP:0002086 abnormal extraembryonic tissue morphology
|
|
GS180977: GO:0045184 establishment of protein localization
|
|
GS166142: MP:0006237 abnormal choroid vasculature morphology
|
|
GS123765: Dobutamine interacting genes (MeSH:D004280) in CTD
|
|
GS166187: MP:0000322 increased granulocyte number
|
|
GS126498: Dextroamphetamine interacting genes (MeSH:D003913) in CTD
|
|
GS210495: GO:0002274 myeloid leukocyte activation
|
|
GS122530: helenalin interacting genes (MeSH:C001329) in CTD
|
|
GS204021: GO:0044707 single-multicellular organism process
|
|
GS205047: GO:0006807 nitrogen compound metabolic process
|
|
GS207672: GO:0002695 negative regulation of leukocyte activation
|
|
GS191626: GO:0032680 regulation of tumor necrosis factor production
|
|
GS167248: MP:0003434 decreased susceptibility to induced choroidal neovascularization
|
|
GS184629: GO:0005515 protein binding
|
|
GS190178: GO:0051050 positive regulation of transport
|
|
GS169603: MP:0001672 abnormal embryogenesis/ development
|
|
GS166404: MP:0002113 abnormal skeleton development
|
|
GS205458: GO:0050715 positive regulation of cytokine secretion
|
|
GS125028: glucuronoxylomannan interacting genes (MeSH:C027478) in CTD
|
|
GS163358: MP:0008559 abnormal interferon-gamma secretion
|
|
GS129179: spontaneous crescentic glomerulonephritis QTL 2 (Scgq2 Published QTL Chr 1)
|
|
GS166978: MP:0005179 decreased circulating cholesterol level
|
|
GS194637: GO:0045347 negative regulation of MHC class II biosynthetic process
|
|
GS127240: Acetaminophen interacting genes (MeSH:D000082) in CTD
|
|
GS167324: MP:0003948 abnormal gas homeostasis
|
|
GS126639: Danazol interacting genes (MeSH:D003613) in CTD
|
|
GS207863: GO:0009057 macromolecule catabolic process
|
|
GS123520: oren gedoku to interacting genes (MeSH:C061676) in CTD
|
|
GS197750: GO:0042536 negative regulation of tumor necrosis factor biosynthetic process
|
|
GS164667: MP:0005041 abnormal antigen presentation via MHC class II
|
|
GS168269: MP:0002434 abnormal T-helper 2 cell morphology
|
|
GS164032: MP:0004811 abnormal neuron physiology
|
|
GS186488: GO:0048513 organ development
|
|
GS170600: MP:0005620 abnormal muscle contractility
|
|
GS170601: MP:0005621 abnormal cell physiology
|
|
GS185794: GO:0045019 negative regulation of nitric oxide biosynthetic process
|
|
GS197665: GO:0051248 negative regulation of protein metabolic process
|
|
GS169095: MP:0004924 abnormal behavior
|
|
GS206001: GO:0030886 negative regulation of myeloid dendritic cell activation
|
|
GS169836: MP:0005388 respiratory system phenotype
|
|
GS165983: MP:0008466 enlarged mesenteric lymph nodes
|
|
GS187293: GO:0009611 response to wounding
|
|
GS166718: MP:0002169 no abnormal phenotype detected
|
|
GS205820: GO:0033036 macromolecule localization
|
|
GS202798: GO:0051048 negative regulation of secretion
|
|
GS196806: GO:0032502 developmental process
|
|
GS206618: GO:0050793 regulation of developmental process
|
|
GS170301: MP:0005617 increased susceptibility to type IV hypersensitivity reaction
|
|
GS126863: resiniferatoxin interacting genes (MeSH:C024353) in CTD
|
|
GS168273: MP:0002432 abnormal CD4-positive T cell morphology
|
|
GS167994: MP:0002405 respiratory system inflammation
|
|
GS170044: MP:0008874 decreased physiological sensitivity to xenobiotic
|
|
GS180689: GO:0060670 branching involved in labyrinthine layer morphogenesis
|
|
GS166891: MP:0003795 abnormal bone structure
|
|
GS186642: GO:0051707 response to other organism
|
|
GS164182: MP:0000489 abnormal large intestine morphology
|
|
GS201592: GO:0009617 response to bacterium
|
|
GS206715: GO:0051674 localization of cell
|
|
GS193484: GO:0032615 interleukin-12 production
|
|
GS194172: GO:0006915 apoptotic process
|
|
GS206299: GO:0032607 interferon-alpha production
|
|
GS164022: MP:0008246 abnormal leukocyte morphology
|
|
GS194586: GO:0002376 immune system process
|
|
GS209009: GO:1901576 organic substance biosynthetic process
|
|
GS126106: Ketoprofen interacting genes (MeSH:D007660) in CTD
|
|
GS182705: GO:0051173 positive regulation of nitrogen compound metabolic process
|
|
GS197644: GO:0006954 inflammatory response
|
|
GS208368: GO:0045354 regulation of interferon-alpha biosynthetic process
|
|
GS204036: GO:0045321 leukocyte activation
|
|
GS210579: GO:0051649 establishment of localization in cell
|
|
GS126599: Aluminum Oxide interacting genes (MeSH:D000537) in CTD
|
|
GS170104: MP:0003723 abnormal long bone morphology
|
|
GS184289: GO:0050707 regulation of cytokine secretion
|
|
GS1035: High-priority Candidate Genes for Human Neuropathic Pain
|
|
GS185960: GO:0051048 negative regulation of secretion
|
|
GS191941: GO:0032720 negative regulation of tumor necrosis factor production
|
|
GS126706: Mercury interacting genes (MeSH:D008628) in CTD
|
|
GS127109: Antimony Sodium Gluconate interacting genes (MeSH:D000967) in CTD
|
|
GS136838: trypansomiasis infection response 3b (Tir3b, Published QTL Chr 1)
|
|
GS166598: MP:0005332 abnormal amino acid level
|
|
GS182673: GO:0006508 proteolysis
|
|
GS164742: MP:0001732 postnatal growth retardation
|
|
GS162833: MP:0010124 decreased bone mineral content
|
|
GS163356: MP:0008552 abnormal circulating tumor necrosis factor level
|
|
GS170414: MP:0008076 abnormal CD4-positive T cell differentiation
|
|
GS183756: GO:0010605 negative regulation of macromolecule metabolic process
|
|
GS124583: L 663536 interacting genes (MeSH:C060893) in CTD
|
|
GS189546: GO:0002440 production of molecular mediator of immune response
|
|
GS207071: GO:0051050 positive regulation of transport
|
|
GS209714: GO:0034504 protein localization to nucleus
|
|
GS207457: GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
|
|
GS206111: GO:0097285 cell-type specific apoptotic process
|
|
GS168750: MP:0002191 abnormal artery morphology
|
|
GS180476: GO:0070227 lymphocyte apoptotic process
|
|
GS205781: GO:0051384 response to glucocorticoid stimulus
|
|
GS207175: GO:0050868 negative regulation of T cell activation
|
|
GS163902: MP:0000490 abnormal crypts of Lieberkuhn morphology
|
|
GS167098: MP:0001819 abnormal immune cell physiology
|
|
GS177356: GO:0003674 molecular_function
|
|
GS207940: GO:0005125 cytokine activity
|
|
GS191722: GO:0008285 negative regulation of cell proliferation
|
|
GS177894: GO:0045346 regulation of MHC class II biosynthetic process
|
|
GS177717: GO:0051239 regulation of multicellular organismal process
|
|
GS201900: GO:0042991 transcription factor import into nucleus
|
|
GS167708: MP:0002412 increased susceptibility to bacterial infection
|
|
GS196837: GO:0042110 T cell activation
|
|
GS194647: GO:0071495 cellular response to endogenous stimulus
|
|
GS188410: GO:0032774 RNA biosynthetic process
|
|
GS191727: GO:0008283 cell proliferation
|
|
GS164446: MP:0005195 abnormal posterior eye segment morphology
|
|
GS202005: GO:0006605 protein targeting
|
|
GS201261: GO:0009895 negative regulation of catabolic process
|
|
GS210095: GO:0032943 mononuclear cell proliferation
|
|
GS189939: GO:0032649 regulation of interferon-gamma production
|
|
GS203072: GO:0090304 nucleic acid metabolic process
|
|
GS125927: roquinimex interacting genes (MeSH:C045282) in CTD
|
|
GS189580: GO:0042089 cytokine biosynthetic process
|
|
GS207097: GO:0008083 growth factor activity
|
|
GS123947: N-(4-O-glycerol-3-methoxybenzyl)nonivamide interacting genes (MeSH:C080418) in CTD
|
|
GS164046: MP:0001968 abnormal touch/ nociception
|
|
GS183329: GO:0070851 growth factor receptor binding
|
|
GS166070: MP:0008873 increased physiological sensitivity to xenobiotic
|
|
GS187193: GO:0044057 regulation of system process
|
|
GS196715: GO:0042348 NF-kappaB import into nucleus
|
|
GS184382: GO:0042107 cytokine metabolic process
|
|
GS182242: GO:0045348 positive regulation of MHC class II biosynthetic process
|
|
GS169531: MP:0005391 vision/eye phenotype
|
|
GS167545: MP:0001793 altered susceptibility to infection
|
|
GS190771: GO:0002697 regulation of immune effector process
|
|
GS166889: MP:0003797 abnormal compact bone morphology
|
|
GS168275: MP:0002439 abnormal plasma cell morphology
|
|
GS168848: MP:0002452 abnormal antigen presenting cell physiology
|
|
GS162841: MP:0009481 cecum inflammation
|
|
GS135872: femur geometry 1 (Fmgty1, Published QTL Chr 1)
|
|
GS199468: GO:0006508 proteolysis
|
|
GS168705: MP:0008671 abnormal interleukin-13 secretion
|
|
GS126291: Dactinomycin interacting genes (MeSH:D003609) in CTD
|
|
GS165809: MP:0002864 abnormal ocular fundus morphology
|
|
GS166972: MP:0005178 increased circulating cholesterol level
|
|
GS182981: GO:0043067 regulation of programmed cell death
|
|
GS185961: GO:0051049 regulation of transport
|
|
GS199113: GO:0015031 protein transport
|
|
GS205758: GO:0016477 cell migration
|
|
GS167040: MP:0003887 increased hepatocyte apoptosis
|
|
GS193237: GO:0031325 positive regulation of cellular metabolic process
|
|
GS195214: GO:0009987 cellular process
|
|
GS207177: GO:0050864 regulation of B cell activation
|
|
GS210430: GO:0032615 interleukin-12 production
|
|
GS163934: MP:0001764 abnormal homeostasis
|
|
GS194475: GO:0046823 negative regulation of nucleocytoplasmic transport
|
|
GS200648: GO:0044260 cellular macromolecule metabolic process
|
|
GS165525: MP:0010768 mortality/aging
|
|
GS193639: GO:0051641 cellular localization
|
|
GS126349: Peptidoglycan interacting genes (MeSH:D010457) in CTD
|
|
GS203318: GO:0042035 regulation of cytokine biosynthetic process
|
|
GS169025: MP:0001657 abnormal induced morbidity/mortality
|
|
GS121615: U 75302 interacting genes (MeSH:C062137) in CTD
|
|
GS188478: GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
|
|
GS199262: GO:0032695 negative regulation of interleukin-12 production
|
|
GS124173: R 848 interacting genes (MeSH:C402365) in CTD
|
|
GS206814: GO:0032647 regulation of interferon-alpha production
|
|
GS203642: GO:0006725 cellular aromatic compound metabolic process
|
|
GS209385: GO:0044403 symbiosis, encompassing mutualism through parasitism
|
|
GS170151: MP:0001716 abnormal placenta labyrinth morphology
|
|
GS186472: GO:0042036 negative regulation of cytokine biosynthetic process
|
|
GS190050: GO:0051223 regulation of protein transport
|
|
GS164770: MP:0009250 abnormal appendicular skeleton morphology
|
|
GS201025: GO:0071702 organic substance transport
|
|
GS84106: alcohol preference on Chr1 (Published QTL, Chr 1)
|
|
GS122250: Hexachlorobenzene interacting genes (MeSH:D006581) in CTD
|
|
GS207923: GO:0034641 cellular nitrogen compound metabolic process
|
|
GS169335: MP:0005546 choroidal neovascularization
|
|
GS168166: MP:0009345 abnormal trabecular bone thickness
|
|
GS204720: GO:0032689 negative regulation of interferon-gamma production
|
|
GS182990: GO:0043069 negative regulation of programmed cell death
|
|
GS194040: GO:1901360 organic cyclic compound metabolic process
|
|
GS207069: GO:0051052 regulation of DNA metabolic process
|
|
GS136607: splenomegaly-NZB x NZW 1 (Sbw1, Published QTL Chr 1)
|
|
GS193009: GO:0042127 regulation of cell proliferation
|
|
GS135910: G protein deficiency-induced colitis 2 (Gpdc2, Published QTL Chr 1)
|
|
GS163496: MP:0003303 peritoneal inflammation
|
|
GS189133: GO:0030885 regulation of myeloid dendritic cell activation
|
|
GS201899: GO:0042990 regulation of transcription factor import into nucleus
|
|
GS164782: MP:0009543 abnormal thymus corticomedullary boundary morphology
|
|
GS167629: MP:0005466 abnormal T-helper 2 physiology
|
|
GS190067: GO:0018130 heterocycle biosynthetic process
|
|
GS162837: MP:0010122 abnormal bone mineral content
|
|
GS186530: GO:0002683 negative regulation of immune system process
|
|
GS197948: GO:0002285 lymphocyte activation involved in immune response
|
|
GS164299: MP:0005042 abnormal level of surface class II molecules
|
|
GS205266: GO:0032774 RNA biosynthetic process
|
|
GS195977: GO:0007154 cell communication
|
|
GS206418: GO:0002443 leukocyte mediated immunity
|
|
GS193923: GO:0042092 type 2 immune response
|
|
GS200855: GO:0002875 negative regulation of chronic inflammatory response to antigenic stimulus
|
|
GS185013: GO:0002739 regulation of cytokine secretion involved in immune response
|
|
GS194905: GO:0008219 cell death
|
|
GS194267: GO:0043170 macromolecule metabolic process
|
|
GS180452: GO:0044237 cellular metabolic process
|
|
GS183630: GO:0002682 regulation of immune system process
|
|
GS203827: GO:0051169 nuclear transport
|
|
GS164694: MP:0005048 thrombosis
|
|
GS206953: GO:0018130 heterocycle biosynthetic process
|
|
GS203057: GO:0048518 positive regulation of biological process
|
|
GS124457: Mustard Gas interacting genes (MeSH:D009151) in CTD
|
|
GS208787: GO:0034613 cellular protein localization
|
|
GS200275: GO:0014070 response to organic cyclic compound
|
|
GS194499: GO:0044271 cellular nitrogen compound biosynthetic process
|
|
GS122242: Ceftazidime interacting genes (MeSH:D002442) in CTD
|
|
GS180164: GO:0008150 biological_process
|
|
GS163540: MP:0011396 abnormal sleep behavior
|
|
GS162899: MP:0003982 increased cholesterol level
|
|
GS177531: GO:0043170 macromolecule metabolic process
|
|
GS170742: MP:0005023 abnormal wound healing
|
|
GS165437: MP:0000438 abnormal cranium morphology
|
|
GS163903: MP:0000491 crypts of Lieberkuhn abscesses
|
|
GS164952: MP:0001501 abnormal sleep pattern
|
|
GS205255: GO:0044238 primary metabolic process
|
|
GS207293: GO:0032879 regulation of localization
|
|
GS124286: Benzene interacting genes (MeSH:D001554) in CTD
|
|
GS177214: GO:0006366 transcription from RNA polymerase II promoter
|
|
GS169917: MP:0010155 abnormal intestine physiology
|
|
GS207174: GO:0050869 negative regulation of B cell activation
|
|
GS186562: GO:0009653 anatomical structure morphogenesis
|
|
GS123048: Tretinoin interacting genes (MeSH:D014212) in CTD
|
|
GS207858: GO:0009059 macromolecule biosynthetic process
|
|
GS208903: GO:0071219 cellular response to molecule of bacterial origin
|
|
GS121802: Epinephrine interacting genes (MeSH:D004837) in CTD
|
|
GS122892: 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC interacting genes (MeSH:C432747) in CTD
|
|
GS192321: GO:0050728 negative regulation of inflammatory response
|
|
GS123676: Methylene Chloride interacting genes (MeSH:D008752) in CTD
|
|
GS165417: MP:0002493 increased IgG level
|
|
GS190954: GO:0009056 catabolic process
|
|
GS166472: MP:0004991 decreased bone strength
|
|
GS200602: GO:0044267 cellular protein metabolic process
|
|
GS163568: MP:0002551 abnormal blood coagulation
|
|
GS209953: GO:0042129 regulation of T cell proliferation
|
|
GS204929: GO:0042176 regulation of protein catabolic process
|
|
GS187616: GO:0070663 regulation of leukocyte proliferation
|
|
GS124724: Thalidomide interacting genes (MeSH:D013792) in CTD
|
|
GS198204: GO:0032880 regulation of protein localization
|
|
GS202169: GO:0045190 isotype switching
|
|
GS208365: GO:0045355 negative regulation of interferon-alpha biosynthetic process
|
|
GS193575: GO:0045428 regulation of nitric oxide biosynthetic process
|
|
GS183514: GO:0019219 regulation of nucleobase-containing compound metabolic process
|
|
GS163681: MP:0008566 increased interferon-gamma secretion
|
|
GS183848: GO:0044260 cellular macromolecule metabolic process
|
|
GS186757: GO:0034654 nucleobase-containing compound biosynthetic process
|
|
GS190283: GO:0050866 negative regulation of cell activation
|
|
GS122909: Clonidine interacting genes (MeSH:D003000) in CTD
|
|
GS123320: Interferon-alpha interacting genes (MeSH:D016898) in CTD
|
|
GS166825: MP:0000462 abnormal digestive system morphology
|
|
GS169304: MP:0008251 abnormal phagocyte morphology
|
|
GS178904: GO:0061138 morphogenesis of a branching epithelium
|
|
GS180878: GO:0051246 regulation of protein metabolic process
|
|
GS126579: Biliverdine interacting genes (MeSH:D001664) in CTD
|
|
GS166412: MP:0002118 abnormal lipid homeostasis
|
|
GS204261: GO:0000018 regulation of DNA recombination
|
|
GS209025: GO:0019233 sensory perception of pain
|
|
GS124648: Lipopolysaccharides interacting genes (MeSH:D008070) in CTD
|
|
GS198685: GO:0048522 positive regulation of cellular process
|
|
GS166120: MP:0002106 abnormal muscle physiology
|
|
GS170086: MP:0000703 abnormal thymus morphology
|
|
GS201949: GO:0044699 single-organism process
|
|
GS194734: GO:0030162 regulation of proteolysis
|
|
GS209256: GO:0050728 negative regulation of inflammatory response
|
|
GS190397: GO:0032879 regulation of localization
|
|
GS170089: MP:0000706 small thymus
|
|
GS208954: GO:0006139 nucleobase-containing compound metabolic process
|
|
GS200015: GO:0001816 cytokine production
|
|
GS122358: Diazoxide interacting genes (MeSH:D003981) in CTD
|
|
GS187111: GO:0046209 nitric oxide metabolic process
|
|
GS197488: GO:0060670 branching involved in labyrinthine layer morphogenesis
|
|
GS165739: MP:0008477 decreased spleen red pulp amount
|
|
GS189244: GO:0097285 cell-type specific apoptotic process
|
|
GS181854: GO:0045926 negative regulation of growth
|
|
GS188195: GO:0006809 nitric oxide biosynthetic process
|
|
GS168549: MP:0000477 abnormal intestine morphology
|
|
GS169840: MP:0003711 pathological neovascularization
|
|
GS190177: GO:0051051 negative regulation of transport
|
|
GS190769: GO:0002695 negative regulation of leukocyte activation
|
|
GS124919: Butylated Hydroxytoluene interacting genes (MeSH:D002084) in CTD
|
|
GS206935: GO:0051224 negative regulation of protein transport
|
|
GS163923: MP:0002896 abnormal bone mineralization
|
|
GS190950: GO:0009059 macromolecule biosynthetic process
|
|
GS181568: GO:0006357 regulation of transcription from RNA polymerase II promoter
|
|
GS199020: GO:0002366 leukocyte activation involved in immune response
|
|
GS123883: Methylnitrosourea interacting genes (MeSH:D008770) in CTD
|
|
GS163353: MP:0008551 abnormal circulating interferon-gamma level
|
|
GS163295: MP:0000219 increased neutrophil cell number
|
|
GS178461: GO:0009987 cellular process
|
|
GS122587: Galactosamine interacting genes (MeSH:D005688) in CTD
|
|
GS166380: MP:0008872 abnormal physiological response to xenobiotic
|
|
GS165620: MP:0008125 abnormal dendritic cell number
|
|
GS184284: GO:0050708 regulation of protein secretion
|
|
GS204284: GO:0031644 regulation of neurological system process
|
|
GS177856: GO:0002902 regulation of B cell apoptotic process
|
|
GS207182: GO:0050863 regulation of T cell activation
|
|
GS168849: MP:0002453 abnormal B lymphocyte antigen presentation
|
|
GS191436: GO:0005141 interleukin-10 receptor binding
|
|
GS210507: GO:0006950 response to stress
|
|
GS124185: Plant Extracts interacting genes (MeSH:D010936) in CTD
|
|
GS167941: MP:0001970 abnormal pain threshold
|
|
GS199467: GO:0006509 membrane protein ectodomain proteolysis
|
|
GS135489: bone response to mechanical loading 9 (Brml9, Published QTL Chr 1)
|
|
GS162984: MP:0001800 abnormal humoral immune response
|
|
GS169973: MP:0002006 tumorigenesis
|
|
GS192770: GO:0050663 cytokine secretion
|
|
GS201373: GO:0016447 somatic recombination of immunoglobulin gene segments
|
|
GS201728: GO:0002250 adaptive immune response
|
|
GS188072: GO:0042177 negative regulation of protein catabolic process
|
|
GS181892: GO:0048523 negative regulation of cellular process
|
|
GS193268: GO:0005575 cellular_component
|
|
GS123865: catechol interacting genes (MeSH:C034221) in CTD
|
|
GS188190: GO:0006807 nitrogen compound metabolic process
|
|
GS135800: ethanol induced loss of righting response 1 (Elorr1, Published QTL Chr 1)
|
|
GS170705: MP:0008092 abnormal T-helper 2 cell differentiation
|
|
GS164162: MP:0008704 abnormal interleukin-6 secretion
|
|
GS204317: GO:0009725 response to hormone stimulus
|
|
GS193151: GO:0032940 secretion by cell
|
|
GS199019: GO:0002367 cytokine production involved in immune response
|
|
GS200125: GO:0070851 growth factor receptor binding
|
|
GS207797: GO:0030154 cell differentiation
|
|
GS165656: MP:0003025 increased vasoconstriction
|
|
GS190376: GO:0042742 defense response to bacterium
|
|
GS207581: GO:0007275 multicellular organismal development
|
|
GS184219: GO:0071706 tumor necrosis factor superfamily cytokine production
|
|
GS169589: MP:0008713 abnormal cytokine level
|
|
GS163271: MP:0006042 increased apoptosis
|
|
GS199062: GO:0045351 type I interferon biosynthetic process
|
|
GS164113: MP:0002534 abnormal type IV hypersensitivity reaction
|
|
GS205002: GO:0048856 anatomical structure development
|
|
GS210240: GO:0002861 regulation of inflammatory response to antigenic stimulus
|
|
GS125792: Ethanol interacting genes (MeSH:D000431) in CTD
|
|
GS135921: growth traits 1 (Gwth1, Published QTL Chr 1)
|
|
GS163852: MP:0001544 abnormal cardiovascular system physiology
|
|
GS165131: MP:0008596 increased circulating interleukin-6 level
|
|
GS202188: GO:0044248 cellular catabolic process
|
|
GS163263: MP:0003762 abnormal immune organ physiology
|
|
GS184457: GO:0009895 negative regulation of catabolic process
|
|
GS166746: MP:0002224 abnormal spleen size
|
|
GS201869: GO:0008104 protein localization
|
|
GS123595: Progesterone interacting genes (MeSH:D011374) in CTD
|
|
GS193518: GO:0060711 labyrinthine layer development
|
|
GS193757: GO:0032635 interleukin-6 production
|
|
GS201730: GO:0002252 immune effector process
|
|
GS207857: GO:0009058 biosynthetic process
|
|
GS170358: MP:0001823 thymus hypoplasia
|
|
GS163529: MP:0002957 intestinal adenocarcinoma
|
|
GS201142: GO:0002200 somatic diversification of immune receptors
|
|
GS164101: MP:0003043 hypoalgesia
|
|
GS205165: GO:0010243 response to organic nitrogen
|
|
GS165657: MP:0003026 decreased vasoconstriction
|
|
GS165528: MP:0005379 endocrine/exocrine gland phenotype
|
|
GS170655: MP:0001835 abnormal antigen presentation
|
|
GS163956: MP:0011180 abnormal hematopoietic cell number
|
|
GS167404: MP:0004189 abnormal alveolar process morphology
|
|
GS169835: MP:0005389 reproductive system phenotype
|
|
GS193140: GO:0044144 modulation of growth of symbiont involved in interaction with host
|
|
GS135553: CD8 memory T cell subset 2 (Cd8mts2, Published QTL Chr 1)
|
|
GS125829: CGP 57380 interacting genes (MeSH:C466997) in CTD
|
|
GS201023: GO:0071704 organic substance metabolic process
|
|
GS166706: MP:0002166 altered tumor susceptibility
|
|
GS188594: GO:0050710 negative regulation of cytokine secretion
|
|
GS194385: GO:0043627 response to estrogen stimulus
|
|
GS124165: Hydrogen Peroxide interacting genes (MeSH:D006861) in CTD
|
|
GS126989: Hydralazine interacting genes (MeSH:D006830) in CTD
|
|
GS206932: GO:0051220 cytoplasmic sequestering of protein
|
|
GS201132: GO:0010646 regulation of cell communication
|
|
GS184566: GO:0019538 protein metabolic process
|
|
GS121272: methyldithiocarbamate interacting genes (MeSH:C008435) in CTD
|
|
GS202797: GO:0051047 positive regulation of secretion
|
|
GS124881: N-bromotaurine interacting genes (MeSH:C052954) in CTD
|
|
GS164598: MP:0002330 abnormal bronchial provocation
|
|
GS125650: Pentoxifylline interacting genes (MeSH:D010431) in CTD
|
|
GS201191: GO:0042100 B cell proliferation
|
|
GS202511: GO:0071391 cellular response to estrogen stimulus
|
|
GS124078: methyl isocyanate interacting genes (MeSH:C008461) in CTD
|
|
GS179517: GO:0012501 programmed cell death
|
|
GS167997: MP:0002406 increased susceptibility to infection
|
|
GS169291: MP:0005094 abnormal T cell proliferation
|
|
GS186227: GO:0090304 nucleic acid metabolic process
|
|
GS201189: GO:0042107 cytokine metabolic process
|
|
GS167991: MP:0002401 abnormal lymphopoiesis
|
|
GS204612: GO:0019222 regulation of metabolic process
|
|
GS163106: MP:0008548 abnormal circulating interferon level
|
|
GS210168: GO:0030098 lymphocyte differentiation
|
|
GS170416: MP:0008074 increased CD4-positive T cell number
|
|
GS166536: MP:0004504 decreased incidence of UV-induced tumors
|
|
GS208879: GO:0032720 negative regulation of tumor necrosis factor production
|
|
GS127139: Indomethacin interacting genes (MeSH:D007213) in CTD
|
|
GS186471: GO:0042035 regulation of cytokine biosynthetic process
|
|
GS185054: GO:0008104 protein localization
|
|
GS169695: MP:0004946 abnormal regulatory T cell physiology
|
|
GS184285: GO:0050709 negative regulation of protein secretion
|
|
GS123171: hydroxyhydroquinone interacting genes (MeSH:C013038) in CTD
|
|
GS163857: MP:0005065 abnormal neutrophil morphology
|
|
GS209072: GO:0045861 negative regulation of proteolysis
|
|
GS181267: GO:0048568 embryonic organ development
|
|
GS165421: MP:0002497 increased IgE level
|
|
GS169293: MP:0005098 abnormal choroid morphology
|
|
GS177862: GO:0001775 cell activation
|
|
GS164554: MP:0004876 decreased mean systemic arterial blood pressure
|
|
GS210508: GO:0043901 negative regulation of multi-organism process
|
|
GS204819: GO:0002819 regulation of adaptive immune response
|
|
GS200844: GO:0031347 regulation of defense response
|
|
GS163820: MP:0002875 decreased erythrocyte cell number
|
|
GS167025: MP:0003953 abnormal hormone level
|
|
GS164593: MP:0002335 decreased airway responsiveness
|
|
GS164133: MP:0005076 abnormal cell differentiation
|
|
GS170748: MP:0005025 abnormal response to infection
|
|
GS121893: Vitamin E interacting genes (MeSH:D014810) in CTD
|
|
GS210099: GO:0032944 regulation of mononuclear cell proliferation
|
|
GS168563: MP:0002425 altered susceptibility to autoimmune disorder
|
|
GS209225: GO:0007600 sensory perception
|
|
GS169133: MP:0002442 abnormal leukocyte physiology
|
|
GS206300: GO:0032606 type I interferon production
|
|
GS183425: GO:0043900 regulation of multi-organism process
|
|
GS203607: GO:0034654 nucleobase-containing compound biosynthetic process
|
|
GS185033: GO:0048598 embryonic morphogenesis
|
|
GS192074: GO:1901575 organic substance catabolic process
|
|
GS205333: GO:0032269 negative regulation of cellular protein metabolic process
|
|
GS123070: trimellitic anhydride interacting genes (MeSH:C015559) in CTD
|
|
GS178155: GO:0008219 cell death
|
|
GS189112: GO:0070201 regulation of establishment of protein localization
|
|
GS203494: GO:0051704 multi-organism process
|
|
GS189374: GO:0042981 regulation of apoptotic process
|
|
GS122319: 2,3-bis(palmitoyloxy)-2-propyl-1-palmitoylcysteine interacting genes (MeSH:C069172) in CTD
|
|
GS168710: MP:0001648 abnormal apoptosis
|
|
GS183216: GO:0001816 cytokine production
|
|
GS164596: MP:0002332 abnormal exercise endurance
|
|
GS169422: MP:0006173 abnormal myeloid dendritic cell morphology
|
|
GS196790: GO:0046903 secretion
|
|
GS185585: GO:0044710 single-organism metabolic process
|
|
GS208362: GO:0005141 interleukin-10 receptor binding
|
|
GS168573: MP:0006060 increased cerebral infarction size
|
|
GS187708: GO:0009893 positive regulation of metabolic process
|
|
GS126878: Toluene 2,4-Diisocyanate interacting genes (MeSH:D014051) in CTD
|
|
GS121419: Terfenadine interacting genes (MeSH:D016593) in CTD
|
|
GS193632: GO:0051649 establishment of localization in cell
|
|
GS198786: GO:0002544 chronic inflammatory response
|
|
GS122222: araldite interacting genes (MeSH:C005752) in CTD
|
|
GS136332: non-insulin-dependent diabetes mellitus 6 (Nidd6, Published QTL Chr 1)
|
|
GS121731: Diclofenac interacting genes (MeSH:D004008) in CTD
|
|
GS197349: GO:0050776 regulation of immune response
|
|
GS195712: GO:0060669 embryonic placenta morphogenesis
|
|
GS136370: obesity QTL 17 (Obq17, Published QTL Chr 1)
|
|
GS203046: GO:0060326 cell chemotaxis
|
|
GS189398: GO:0044110 growth involved in symbiotic interaction
|
|
GS184709: GO:0002439 chronic inflammatory response to antigenic stimulus
|
|
GS206354: GO:0023057 negative regulation of signaling
|
|
GS122027: hydroquinone interacting genes (MeSH:C031927) in CTD
|
|
GS194588: GO:0002374 cytokine secretion involved in immune response
|
|
GS163355: MP:0008553 increased circulating tumor necrosis factor level
|
|
GS201092: GO:0050708 regulation of protein secretion
|
|
GS164040: MP:0003856 abnormal hindlimb stylopod morphology
|
|
GS204479: GO:0070663 regulation of leukocyte proliferation
|
|
GS184883: GO:0010942 positive regulation of cell death
|
|
GS167222: MP:0005311 abnormal circulating amino acid level
|
|
GS198572: GO:0010604 positive regulation of macromolecule metabolic process
|
|
GS201924: GO:0044126 regulation of growth of symbiont in host
|
|
GS184317: GO:0009790 embryo development
|
|
GS167077: MP:0008082 increased single-positive T cell number
|
|
GS182672: GO:0006509 membrane protein ectodomain proteolysis
|
|
GS203383: GO:0009306 protein secretion
|
|
GS199040: GO:0045348 positive regulation of MHC class II biosynthetic process
|
|
GS164183: MP:0000488 abnormal intestinal epithelium morphology
|
|
GS207070: GO:0051051 negative regulation of transport
|
|
GS170643: MP:0004752 decreased length of allograft survival
|
|
GS169828: MP:0005386 behavior/neurological phenotype
|
|
GS199498: GO:0051170 nuclear import
|
|
GS194632: GO:0045342 MHC class II biosynthetic process
|
|
GS164669: MP:0010292 increased alimentary system tumor incidence
|
|
GS136837: trypansomiasis infection response 3a (Tir3a, Published QTL Chr 1)
|
|
GS167626: MP:0005463 abnormal CD4-positive T cell physiology
|
|
GS202415: GO:0044710 single-organism metabolic process
|
|
GS125893: Tetradecanoylphorbol Acetate interacting genes (MeSH:D013755) in CTD
|
|
GS206544: GO:2000112 regulation of cellular macromolecule biosynthetic process
|
|
GS169832: MP:0005381 digestive/alimentary phenotype
|
|
GS123113: monocyte locomotion inhibitory factor interacting genes (MeSH:C430647) in CTD
|
|
GS127334: methylene bis(4-cyclohexylisocyanate) interacting genes (MeSH:C013606) in CTD
|
|
GS170411: MP:0008073 abnormal CD4-positive T cell number
|
|
GS122916: Clenbuterol interacting genes (MeSH:D002976) in CTD
|
|
GS198684: GO:0048523 negative regulation of cellular process
|
|
GS165474: MP:0002723 abnormal immune serum protein physiology
|
|
GS167627: MP:0005460 abnormal leukopoiesis
|
|
GS210177: GO:0031329 regulation of cellular catabolic process
|
|
GS197669: GO:0051246 regulation of protein metabolic process
|
|
GS210586: GO:0051641 cellular localization
|
|
GS185192: GO:0031348 negative regulation of defense response
|
|
GS199501: GO:0051173 positive regulation of nitrogen compound metabolic process
|
|
GS167656: MP:0001943 abnormal respiration
|
|
GS185489: GO:0046651 lymphocyte proliferation
|
|
GS200787: GO:0002637 regulation of immunoglobulin production
|
|
GS184318: GO:0009792 embryo development ending in birth or egg hatching
|
|
GS208906: GO:0071216 cellular response to biotic stimulus
|
|
GS122526: phenylmethylpyrazolone interacting genes (MeSH:C005435) in CTD
|
|
GS190955: GO:0009057 macromolecule catabolic process
|
|
GS206329: GO:0060255 regulation of macromolecule metabolic process
|
|
GS165467: MP:0002724 enhanced wound healing
|
|
GS204054: GO:0044057 regulation of system process
|
|
GS126486: 2,4,5,2',4',5'-hexachlorobiphenyl interacting genes (MeSH:C014024) in CTD
|
|
GS165141: MP:0008666 increased interleukin-12a secretion
|
|
GS124335: Copper interacting genes (MeSH:D003300) in CTD
|
|
GS170759: MP:0009625 abnormal abdominal lymph node morphology
|